Description: Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
Home Page: www.tempus.com
600 West Chicago Avenue
Chicago,
IL
60654
United States
Phone:
800 976 5448
Officers
Name | Title |
---|---|
Mr. Eric P. Lefkofsky | Co-Founder, CEO, President & Chairman |
Mr. James Rogers | Chief Financial Officer |
Mr. Ryan Fukushima | Chief Operating Officer |
Mr. Ryan M. Bartolucci CPA | Chief Accounting Officer |
Mr. Shane Colley | Chief Technology Officer |
Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
Mr. Erik Phelps | Executive VP, Assistant Secretary and Chief Administrative & Legal Officer |
Ms. Patty Spiller | Senior Vice President of Marketing |
Ms. Christina Antoniou | Senior VP & Head of Corporate Development |
Ms. Stacey Kraft | Chief People Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 80.5748 |
Price-to-Sales TTM: | 13.295 |
IPO Date: | 2024-06-14 |
Fiscal Year End: | December |
Full Time Employees: | 0 |